LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”)(OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Manish Singh Ph.D., the Company’s President and CEO, will present at the 2nd World Cancer Vaccines Summit at the Radisson Hotel in Boston, MA on Thursday, June 23rd at 2:00 p.m. The presentation titled, "Multiple Antigen Vaccines for Glioblastoma" will feature ICT-107, ImmunoCellular’s dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme(GBM). The presentation will describe ICT-107’s targeting of multiple antigens present on cancer stem cells and daughter cells, the significant improvements observed in progression free and overall survival data following the phase I trial of ICT-107 in newly diagnosed GBM patients, and the multicenter phase II trial currently underway. The Summit brings together leading executives from all major CROs, oncology pharmaceuticals, cancer vaccine biotechs and investigators in the field.
